

ANTARES PHARMA, INC.  
Form 8-K  
November 06, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 6, 2014**

**ANTARES PHARMA, INC.**

**(Exact name of registrant specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**1-32302**  
**(Commission**  
  
**File Number)**

**41-1350192**  
**(I.R.S. Employer**  
  
**Identification No.)**

**100 Princeton South, Suite 300, Ewing, NJ**

**(Address of principal executive offices)**

**Registrant's telephone, including area code: (609) 359-3020**

**08628**

**(Zip Code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a- 12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

On November 6, 2014, Antares Pharma, Inc. (the Company ) issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2014. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific references in such filing.

**Item 7.01 Regulation FD Disclosure.**

As previously announced, the Company will conduct a conference call today, Thursday, November 6, 2014 at 8:30 a.m. ET to discuss results and highlights of the third quarter 2014. A web cast of the conference call will be available on the Investors section of the Company s web site beginning at 8:30 a.m. ET on Thursday, November 6, 2014 and will remain available for future review until November 21, 2014.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated November 6, 2014, issued by Antares Pharma, Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTARES PHARMA, INC.

Date: November 6, 2014

By: /s/ Robert F. Apple

Name: Robert F. Apple

Title: Executive Vice President, acting Chief

Financial Officer

**EXHIBIT INDEX**

**Exhibit**

Exhibit No.	Description
99.1	Press Release, dated November 6, 2014, issued by Antares Pharma, Inc.